Arrowhead Pharmaceuticals (ARWR) is back in focus after two late stage RNA interference programs hit important milestones. Plozasiran delivered positive Phase 3 topline data in severe hypertriglyceridemia, and zodasiran’s Phase 3 YOSEMITE trial has now completed enrollment.

The recent late stage cardiometabolic data appear to be feeding into Arrowhead Pharmaceuticals’ share price momentum, with a 30 day share price return of 7.11% and a 90 day share price return of 17.34%. Over a longer horizon, the total shareholder return over the past year is very large at about 7x. This contrasts with a more moderate 3 year total shareholder return of 161.51% and a 5 year total shareholder return of 30.40%. This suggests most of the move has been concentrated in the recent period as investors reassess Arrowhead’s risk and opportunity mix.

If the Arrowhead story has you looking at RNA and cardiometabolic opportunities, it can also help to see what else is moving in related areas and uncover 41 healthcare AI stocks

For Arrowhead Pharmaceuticals, a roughly 7x one year total shareholder return creates a simple tension. Is this just the opening act for the RNA cardiometabolic thesis, or has the stock already banked most of the upside ahead of current valuation work?

Most Popular Narrative: 3% Undervalued

Arrowhead Pharmaceuticals last closed at $86.22, while the most followed narrative pegs fair value at about $89.08. That gap rests on a very specific view of how the RNA pipeline and margins could evolve over time.

Multiple large pharma collaborations and milestone-generating partnerships (notably with Sarepta, Amgen, Takeda, and Sanofi) provide non-dilutive capital, revenue diversity, and stability independent of volatile equity markets. This supports sustained R&D investments and improves medium-term cash flow visibility.

Want to see what sits behind that fair value for Arrowhead Pharmaceuticals? The narrative leans on brisk revenue growth, margin expansion and a rich profit multiple on future earnings. Curious which assumptions matter most and how stretched those numbers are.

Result: Fair Value of $89.08 (UNDERVALUED)

However, the Arrowhead Pharmaceuticals narrative still leans heavily on partner milestones and assumes smooth progression through late stage trials, so any delay or setback could quickly challenge today’s fair value story.

Another View on Arrowhead Pharmaceuticals’ Valuation

Our DCF model paints a very different picture for Arrowhead Pharmaceuticals. On this view, the stock at $86.22 is trading far below an estimated future cash flow value of $657.27, which screens as heavily undervalued. That kind of gap raises a clear question: Is the market too cautious, or is the model too optimistic?

Next Steps

Uncertain whether the mixed sentiment around Arrowhead Pharmaceuticals points to more room on the upside or a lot of optimism already priced in? Act while the data is fresh by reviewing the balance of 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Arrowhead Pharmaceuticals?

If Arrowhead Pharmaceuticals has sharpened your focus, do not stop here. The market is full of other stocks that could fit your goals and time horizon.

Use the Simply Wall St screener to quickly surface fresh ideas that match how you like to invest, before the next wave of interest rushes in.

• Target potential bargains by scanning for companies that combine quality fundamentals with attractive valuations through the 49 high quality undervalued stocks.
• Strengthen your income approach by reviewing companies with higher yields and resilient payout histories in the 9 dividend fortresses.
• Prioritize resilience by focusing on companies with robust financial footing using the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.